Cyril Konto, M.D. has served as Chief Medical Officer since joining Ichnos and as the company’s Chief Executive Officer since May 2021. Previously, Cyril was Vice President of Clinical Development at Allogene Therapeutics, a spinoff from Pfizer, where he pioneered development of allogeneic CAR T-cell therapies. At Pfizer, he was Executive Director of Early Immuno-oncology Clinical Development. He began his industry career at Bristol Myers Squibb, first in medical affairs, and then in late-stage clinical development as clinical lead for the YERVOY® (ipilimumab) melanoma program. An oncologist by training, Cyril received his medical degree from University René Descartes in Paris and began practicing medicine at Pierre and Marie Curie University, where he held both clinical and academic positions.
What do you dare to imagine?
“A world where, as a result of the collective efforts of Ichnos and others in the oncology community, every cancer patient can be offered a cure.”
Roberto Giovannini, Ph.D., is responsible for leading CMC development at Ichnos Sciences. Roberto has more than 20 years of combined pharmaceutical and academic experience in the biotech sector with a focus on process development, covering all aspects of process development and scale-up. Previously, Roberto held multiple positions at Glenmark Pharmaceuticals and Boehringer Ingelheim, leading chemistry, manufacturing, and control (CMC) development for early- to late-stage development programs. Earlier in his career as a scientist, Roberto was at Bayer HealthCare, where he was in charge of process development for new therapeutics. He has a Ph.D. in purification of proteins from Ecole Polytechnique Fédérale de Lausanne and a master’s degree in chemistry from the University of Geneva.
What do you dare to imagine?
“Developing first-in-class treatments built on science that will make a positive impact on patients’ lives.”
Patricia Jaquet joined Ichnos Sciences in June 2019 as Head of Human Resources for Switzerland and now oversees the function globally. With more than 20 years of experience in Human Resources, Patricia’s responsibilities at Ichnos include providing strategic and operational support to enable employees to give the best of themselves and contribute to the development of new therapies for cancer patients. Prior to Ichnos, she worked at Covance Central Laboratory Services where she held roles of increasing responsibilities in Geneva & Zurich (Switzerland), Indianapolis (USA), Amsterdam (The Netherlands) and Singapore. During her career, Patricia has worked across numerous areas of Human Resources, including strategic HR, organizational development, talent management, employee relations, compensation and benefits, talent acquisition and training & development. She holds a master’s degree in Psychology and a certification in Labor law.
What do you dare to imagine?
“That our continued support enables Ichnos scientists and colleagues to make significant contributions that result in the development of therapies that can transform medicine and lives.”
Lida Pacaud, M.D. is an accomplished physician and expert in oncology drug development. She has served as medical lead for clinical development strategies and execution of phase one to phase three programs. She has successfully delivered clearance of several Investigational New Drug applications for first-in-human CAR-T cell programs and has extensive experience with health authority interactions for marketing authorization submissions and approvals.
Prior to joining Ichnos, Lida served as Vice President, Head of Clinical Development and Medical Affairs at Legend Biotech where she led the Janssen J&J partnership for global development of CARVYKTI (BCMA CAR-T) and established the company’s clinical capabilities for early portfolio pipelines (except China territory).
She also previously worked on development of KYMRIAH (CD19 CAR-T) and AFINITOR (mTOR kinase inhibitor) at Novartis and AVASTIN (VEGF inhibitor mAb) at Hoffman la Roche.
Lida received her medical degree and a certification in pediatrics from Tbilisi State Medical University in Georgia and served as a clinical research physician and investigator at Robert-Debré Hospital in Paris.
What do you dare to imagine?
“Fighting every cancer with a multi-targeting immunotherapy approach to ease daily treatment and make positive impacts on the lives of patients and their families.”
Michael Price serves as our Chief Financial Officer and has more than 25 years of biotechnology and pharmaceutical industry experience. Prior to joining Ichnos, he held the position of Executive Vice President and CFO at Akcea Therapeutics, Inc., where he helped manage all aspects of the business and worked closely with the executive team and independent directors on the Ionis Pharmaceuticals takeover. Prior to Akcea, Michael served as CFO at Novelion Therapeutics, Noven Pharmaceuticals, and Bentley Pharmaceuticals. He is a CPA and began his career with Price Waterhouse, now PWC.
Michael received his bachelor’s degree in accounting from Auburn University and his Master of Business Administration degree from Florida State University.
What do you dare to imagine?
“Working collaboratively to address the unmet needs of oncology patients and their families around the world.”
Dean Thomas is an accomplished life sciences lawyer with a remarkable international career that spans both private practice and industry. With a diverse range of experience across various geographies and technical domains, Dean brings a unique blend of critical reasoning and creative problem-solving to the table. He excels in people management, leading diverse and dispersed teams with a personable and approachable management style.
Dean's extensive career includes roles at prominent healthcare organizations such as Pfizer, Amgen, Glenmark Pharmaceuticals, and Ichnos Sciences, as well as law firms in the UK, USA, Germany, and France. He has successfully led legal and intellectual property teams to address complex issues affecting life sciences companies, particularly in multi-jurisdiction litigation and resolving intricate legal disputes. Dean has also played a pivotal role in orchestrating multiple product launches across the globe.
What do you dare to imagine?
As A.P.J. Abdul Kalam said, “History has proven that those who dare to imagine the impossible are the ones who break all human limitations.”
Eugene Zhukovsky, Ph.D. is a renowned expert in the field of biotechnology, with over 25 years of international experience in the research and development of novel immuno-oncology therapies. His background includes work in discovery, antibody engineering and translational sciences, and he has successfully built drug discovery platforms.
In addition to Dr. Zhukovsky’s scientific expertise, he has demonstrated extensive leadership skills while serving as an executive at several biopharmaceutical companies and he was a major contributor to the development of a product approved for a hematologic malignancy. Prior to joining Ichnos Sciences, Dr. Zhukovsky was the CSO at Affimed, where he led the advancement of candidates from discovery through clinical development. As the Chief Technology Officer at Go Therapeutics, he created a T Cell Engagement platform to enable the leveraging of the company’s unique cancer cell-targeting antibodies. He also served as the CSO at Biomunex Pharmaceuticals, where he focused on immuno-oncology and T cell engagers based on their bispecific antibody platform.
Dr. Zhukovsky was a co-founder and partner at ZM Scientific, and he has published extensively in scientific journals. He is listed as a co-inventor of more than 15 granted patents and patent applications, including several related to the optimization of antibodies targeting CD3, CD19, CD33, and CD40. Dr. Zhukovsky earned a Ph.D. in Biochemistry from Brandeis University and was a postdoctoral fellow at Genentech.
Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals Ltd. He joined in 1998 as Director and took over as Managing Director and CEO in 2001. As Chairman and Managing Director of Glenmark, Glenn oversees all operations of the organization. During his tenure, he transformed Glenmark into a truly global organization with revenues of more than $1 billion and a commercial presence in more than 50 countries. Under his leadership, Glenmark has evolved from a generics business into a research-driven and innovation-led organization. He holds a bachelor’s degree in pharmacy from Mumbai University in India and has a master’s degree in business administration from the Leonard Stern School of Business at New York University. Prior to Glenmark, he worked with Eli Lilly, USA and PricewaterhouseCoopers, USA.
David Lubner has more than 20 years of finance and executive leadership experience and served as Executive Vice President and Chief Financial Officer (CFO) of Ra Pharma, acquired by UCB Pharma in April 2020. Before joining Ra Pharma, David served as Senior Vice President, CFO at Tetraphase Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel antibiotics for the treatment of serious and life-threatening multidrug-resistant (MDR) bacterial infections. He also held CFO roles at PharMetrics, Inc., a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. In addition, David serves on the Board of Directors of Dyne Therapeutics (Nasdaq: DYN), Therapeutics Acquisition Corporation (Nasdaq: RACA), and several other private companies and previously served on the Board of Directors of Nightstar Therapeutics until its acquisition by Biogen in June 2019. He is a Certified Public Accountant (CPA) in the Commonwealth of Massachusetts and a member of the American Institute of CPAs. David received his bachelor’s degree in accounting and business management from Northeastern University and a master’s degree in taxation from Bentley University.
V S Mani is the Executive Director & Global Chief Financial Officer of Glenmark Pharmaceuticals Limited. He is responsible for the company’s worldwide finance operations and secretarial function, including global accounting and financial reporting as well as tax and treasury functions. He is a qualified Chartered Accountant from India and has nearly 30 years of rich industry experience across treasury, taxation (direct, indirect, and international), accounting, financial planning and analysis, secretarial, legal, audits (internal and statutory), risk management, and investor relations. Prior to joining Glenmark in 2017, he was the President-Finance at the Bhartiya Group. He has also held the position of the Chief Financial Officer at Cipla Ltd. and played a key role in the acquisition of various companies in emerging and mature markets for the organization.
Alind Sharma is President and Chief Human Resources Officer of Glenmark Pharmaceuticals Ltd. He is responsible for driving organizational advancement through effective human capital strategy. His areas of focus comprise enriching and developing the organization’s diverse talent, appropriate and timely rewards through robust performance management, leadership development and talent engagement. Previously, Alind served as Vice President of Human Capital at Optum, a part of the United Health Group. He is a graduate of the Indian Institute of Management in Ahmedabad, India.
Lawrence Olanoff is currently an adjunct assistant professor and special advisor to the President for Corporate Relations at the Medical University of South Carolina. Previously, he served as President and Chief Operating Officer for Forest Laboratories, Inc. from 2006 through 2010. From 2005 to 2006, Dr. Olanoff was Chief Executive Officer of Celsion Corporation. He also served as Executive Vice President of Research and Development and Chief Scientific Officer of Forest from 1995 to 2005. Prior to joining Forest, Dr. Olanoff served in senior clinical research roles at Sandoz Pharmaceutical Corporation and at The Upjohn Company. During his pharmaceutical development career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals, either as new chemical entities or as supplemental indications, over a range of therapeutic areas. He serves as a member of the Board of Ironwood Pharmaceuticals as well as several nonprofit organizations. Dr. Olanoff also held past directorships on the Boards of Forest Laboratories, Axovant Sciences Ltd., and the Celsion Corporation. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University, was an internal medicine resident and clinical pharmacology fellow at the Medical University of South Carolina, and is the author of some forty scientific publications on topics including controlled drug delivery, pharmacokinetics, drug metabolism, and clinical toxicology.
Dennis Purcell is the original founder of Aisling Capital LLC and currently serves as a senior advisor. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Dennis served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for more than five years. While at H&Q, he was directly involved with more than 200 completed transactions and supervised more than $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology, and medical products industries. During his tenure, BioWorld Today and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc. Dennis is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering & Biotechnology News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen, and cited as one of the top 100 contributors to the biotechnology industry. He received his master’s degree in business administration from Harvard Business School and his bachelor’s degree in accounting from the University of Delaware.
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
Concerning Your Privacy